Toggle navigation
Home
Search
Services
Blog
Contact
About
New Method of Deglycerolizing Rbcs
Draheim, James E.
Symbiotech, Inc., Wallingford, CT, United States
Search 9 grants from James Draheim
Search grants from Symbiotech, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Adolescent Alcohol Abuse, Traumatic Stress, and Vulnerability to Development of PTSD
Pharmacogenomics of Microtubule Targeting Agents
Clinical and Behavioral Science Training in Aging and Health Disparities
HSC transduction in situ by cellular delivery of integrating viral vectors
Abeta oligomers (ADDLs)in Alzheimers Disease pathology
Recently added grants:
The UCLA HIV/AIDS, Substance Abuse, and Trauma Training Program
Real-time Predictors of Prescription Drug Misuse by College Students and Assessment of Misuse on Their Developmental Trajectories
Mentalizing deficits in cocaine addiction, associations with immune dysregulation and childhood maltreatment
Non-opiate treatment after prenatal opiate exposure to Prevent Postnatal Injury to the Young Brain (No-POPPY)
Individualized assays of supra-threshold hearing deficits
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44HL052355-02
Application #
2421218
Study Section
Special Emphasis Panel (ZRG2-SSS-3 (45))
Project Start
1994-06-01
Project End
1999-08-31
Budget Start
1997-09-01
Budget End
1998-08-31
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Institution
Name
Symbiotech, Inc.
Department
Type
DUNS #
City
Wallingford
State
CT
Country
United States
Zip Code
06492
Related projects
NIH 1998
R44 HL
New Method of Deglycerolizing Rbcs
Draheim, James E. / Symbiotech, Inc.
NIH 1997
R44 HL
New Method of Deglycerolizing Rbcs
Draheim, James E. / Symbiotech, Inc.
Comments
Be the first to comment on James Draheim's grant